Evaluation of in vitro models for screening alkaline phosphatase-mediated bioconversion of phosphate ester prodrugs

Drug Metabolism and Disposition

Volumn 37, Issue 7, 2009, Pages 1443-1447

  Yuan, Haodan ^a   Li, Na ^a   Lai, Yurong ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; FLUCONAZOLE; FOSFLUCONAZOLE; FOSPHENYTOIN SODIUM; PHENYTOIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SCREENING; DRUG TRANSPORT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE MUCOSA; MALE; MICHAELIS CONSTANT; NONHUMAN; PRIORITY JOURNAL; RAT;

ALKALINE PHOSPHATASE; ANIMALS; CACO-2 CELLS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FLUCONAZOLE; HALF-LIFE; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; INTESTINES; MALE; MUCOUS MEMBRANE; PHENYTOIN; PHOSPHATES; PHOSPHORIC ACID ESTERS; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

RATTUS;

EID: 67649398906     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.026245     Document Type: Article

References (19)

1. Amidon GL, Lennernäs H, Shah VP, and Crison JR (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
2. Becker S and Thornton L (2004) Fosamprenavir: advancing HIV protease inhibitor treatment options. Expert Opin Pharmacother 5:1995-2005. (Pubitemid 39236600)
3. Bentley A, Butters M, Green SP, Learmonth WJ, MacRae JA, Morland MC, O'Connor G, and Skuse J (2002) The discovery and process development of a commercial route to the water soluble prodrug, fosfluconazole. Org Proc Res Dev 6:109-112.
4. Boucher BA (1996) Fosphenytoin: a novel phenytoin prodrug. Pharmacotherapy 16:777-791. (Pubitemid 26322182)
5. de Jong RS, Mulder NH, Uges DR, Kaul S, Winograd B, Sleijfer DTh, Groen HJ, Willemse PH, van der Graaf WT, and de Vries EG (1997) Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide. Br J Cancer 75:1660-1666. (Pubitemid 27229058)
6. Fleisher D, Bong R, and Steward BH (1996) Improved oral drug delivery: solubility limitations overcome by the use of prodrugs. Adv Drug Deliv Rev 19:115-130. (Pubitemid 26192965)
7. Fleisher D, Stewart BH, and Amidon GL (1985) Design of prodrugs for improved gastrointestinal absorption by intestinal enzyme targeting. Methods Enzymol 112:360-381. (Pubitemid 15036593)
8. Furfine ES, Baker CT, Hale MR, Reynolds DJ, Salisbury JA, Searle AD, Studenberg SD, Todd D, Tung RD, and Spaltenstein A (2004) Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother 48:791-798. (Pubitemid 38280326)
9. Heimbach T, Oh DM, Li LY, Forsberg M, Savolainen J, Leppänen J, Matsunaga Y, Flynn G, and Fleisher D (2003) Absorption rate limit considerations for oral phosphate prodrugs. Pharm Res 20:848-856. (Pubitemid 36628429)
10. Henthorn PS, Raducha M, Kadesch T, Weiss MJ, and Harris H (1988) Sequence and characterization of the human intestinal alkaline phosphatase gene. J Biol Chem 263:12011-12019. (Pubitemid 18212267)
11. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernäs H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, et al. (2004) Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 1:85-96.
12. Kearney AS and Stella VJ (1992) The in vitro enzymic labilities of chemically distinct phosphomonoester prodrugs. Pharm Res 9:497-503.
13. Lai Y, Bakken AH, and Unadkat JD (2002) Simultaneous expression of hCNT1-CFP and hENT1-YFP in Madin-Darby canine kidney cells. Localization and vectorial transport studies. J Biol Chem 277:37711-37717.
14. Luer MS (1998) Fosphenytoin. Neurol Res 20:178-182.
15. Pinto M, Rabine-Leon S, Appay MD, Kedinger M, Triadou N, Dussaulx E, Louroix B, Simon-Assmann P, Haffen K, Fogh J, et al. (1983) Enterocyte-like differentiation and polarisation of the human colon carcinoma cell line Caco-2 in culture. Biol Cell 47:323-330. (Pubitemid 14236699)
16. Safadi M, Oliyai R, and Stella VJ (1993) Phosphoryloxymethyl carbamates and carbonates-novel water-soluble prodrugs for amines and hindered alcohols. Pharm Res 10:1350-1355. (Pubitemid 23261839)
17. Sobue S, Tan K, Layton G, Eve M, and Sanderson JB (2004) Pharmacokinetics of fosfluconazole and fluconazole following multiple intravenous administration of fosfluconazole in healthy male volunteers. Br J Clin Pharmacol 58:20-25. (Pubitemid 38901462)
18. Vyas DM, Wong H, Crosswell AR, Casazza AM, Knipe J, Mamber SW, and Doyle TW (1993) Synthesis and antitumor evaluation of water soluble Taxol phosphates. Bioorg Med Chem Lett 3:1357-1360. (Pubitemid 23185625)
19. Yamreudeewong W, Lopez-Anaya A, and Rappaport H (1993) Stability of fluconazole in an extemporaneously prepared oral liquid. Am J Hosp Pharm 50:2366-2367. (Pubitemid 23330913)